Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Switzerland's Roche announced on the 12th (local time) that it has signed a contract to acquire the technology for the obesity drug candidate 'petrelintide' from Denmark's biotech Zealand Pharma. If ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Roche's stock rallied in Europe, while ...

Health-care companies fell as traders rotated back into higher risk areas. Swiss drug giant Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.